ERK1/2
proteinERK1/2 kinases transduce activation signals driving platelet aggregation and thrombus formation.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleMAPK signaling mediator downstream of platelet activation and integrin engagement.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresShared / rises in both
R — rupture / Type-I67
C — confounder / Type-II56
A — assay feasibility68
E — evidence strength75
T1DI (composite)28
Specificity differential (R−C)+11.1
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 1
7high-demand / peri-operative stressn/a
Coverage: 3/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 23 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Inhibitory effects of hydrogen on in vitro platelet activation and in vivo prevention of thrombosis formation.Life sciences · 2019 · PMID 31356907 · doi